Published in Arthritis Rheum on January 11, 2012
Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles (2015) 3.02
The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes. EMBO Mol Med (2012) 1.01
Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol (2013) 0.99
Complement in the immunopathogenesis of rheumatic disease. Nat Rev Rheumatol (2012) 0.98
Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. Cell (2016) 0.93
Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus. Immunol Res (2013) 0.90
Anti-DNA antibodies - quintessential biomarkers of SLE. Nat Rev Rheumatol (2015) 0.88
Cause or effect of arteriogenesis: compositional alterations of microparticles from CAD patients undergoing external counterpulsation therapy. PLoS One (2012) 0.86
Proportions of several types of plasma and urine microparticles are increased in patients with rheumatoid arthritis with active disease. Clin Exp Immunol (2015) 0.83
Regulation of chronic inflammatory and immune processes by extracellular vesicles. J Clin Invest (2016) 0.82
The effect of cell death in the initiation of lupus nephritis. Clin Exp Immunol (2015) 0.81
The role of microparticles in the generation of immune complexes in murine lupus. Clin Immunol (2012) 0.81
The role of antigen specificity in the binding of murine monoclonal anti-DNA antibodies to microparticles from apoptotic cells. Clin Immunol (2014) 0.81
Extracellular vesicles in the pathogenesis of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther (2016) 0.80
Microparticles as autoantigens: making immune complexes big. Arthritis Rheum (2012) 0.80
An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis. Cancer Res (2015) 0.80
Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus. Lupus Sci Med (2014) 0.79
The properties of microparticles from RAW 264.7 macrophage cells undergoing in vitro activation or apoptosis. Innate Immun (2013) 0.78
Microparticles That Form Immune Complexes as Modulatory Structures in Autoimmune Responses. Mediators Inflamm (2015) 0.77
Sera from patients with active systemic lupus erythematosus patients enhance the toll-like receptor 4 response in monocyte subsets. J Inflamm (Lond) (2015) 0.76
Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations. Sci Rep (2016) 0.76
Extracellular Vesicles: Evolving Contributors in Autoimmunity. For Immunopathol Dis Therap (2015) 0.75
Complement in Lupus Nephritis: New Perspectives. Kidney Dis (Basel) (2015) 0.75
Characterization of the Proinflammatory Profile of Synovial Fluid-Derived Exosomes of Patients with Osteoarthritis. Mediators Inflamm (2017) 0.75
Circulating DNA in rheumatoid arthritis: pathological changes and association with clinically used serological markers. Arthritis Res Ther (2017) 0.75
Circulating exosomes from patients with systemic lupus erythematosus induce an proinflammatory immune response. Arthritis Res Ther (2016) 0.75
Surface complement C3 fragments and cellular binding of microparticles in patients with SLE. Lupus Sci Med (2017) 0.75
Proteinase 3 Is a Phosphatidylserine-binding Protein That Affects the Production and Function of Microvesicles. J Biol Chem (2016) 0.75
Biomarkers of systemic lupus erythematosus identified using mass spectrometry-based proteomics: a systematic review. J Cell Mol Med (2016) 0.75
A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus. Clin Proteomics (2017) 0.75
Are microparticles the missing link between thrombosis and autoimmune diseases? Involvement in selected rheumatologic diseases. Semin Thromb Hemost (2014) 0.75
Extracellular vesicles as mediators of vascular inflammation in kidney disease. World J Nephrol (2016) 0.75
Extracellular Vesicles as Therapeutic Agents in Systemic Lupus Erythematosus. Int J Mol Sci (2017) 0.75
A low balance between microparticles expressing tissue factor pathway inhibitor and tissue factor is associated with thrombosis in Behçet's Syndrome. Sci Rep (2016) 0.75
Identification of potential saliva and tear biomarkers in primary Sjögren's syndrome, utilising the extraction of extracellular vesicles and proteomics analysis. Arthritis Res Ther (2017) 0.75
Extracellular vesicles in renal disease. Nat Rev Nephrol (2017) 0.75
Distinct proteome pathology of circulating microparticles in systemic lupus erythematosus. Clin Proteomics (2017) 0.75
Acetylated Histones in Apoptotic Microparticles Drive the Formation of Neutrophil Extracellular Traps in Active Lupus Nephritis. Front Immunol (2017) 0.75
Re-Examining Neutrophil Participation in GN. J Am Soc Nephrol (2017) 0.75
Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet (2008) 5.00
A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet (2002) 4.03
Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum (2003) 3.79
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol (2004) 3.07
Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med (2004) 2.62
Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation (2006) 2.58
Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther (2006) 2.18
Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol (2006) 2.14
Pathogenic mechanisms in lupus nephritis: Nucleosomes bind aberrant laminin β1 with high affinity and colocalize in the electron-dense deposits. Arthritis Rheumatol (2014) 2.13
Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol (2012) 2.12
A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet (2008) 1.98
Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet (2007) 1.95
CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement (2013) 1.90
Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken) (2010) 1.89
Toll-like receptor 4 promoter polymorphisms: common TLR4 variants may protect against severe urinary tract infection. PLoS One (2010) 1.82
MicroRNAs in liver disease. Gastroenterology (2012) 1.76
Genetically determined high serum levels of mannose-binding lectin and agalactosyl IgG are associated with ischemic heart disease in rheumatoid arthritis. Arthritis Rheum (2007) 1.70
Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest (2006) 1.69
Complement deficiency states and associated infections. Mol Immunol (2011) 1.57
Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes (2010) 1.56
Genetically reduced antioxidative protection and increased ischemic heart disease risk: The Copenhagen City Heart Study. Circulation (2003) 1.52
Magnetic resonance imaging of wrist and finger joints in healthy subjects occasionally shows changes resembling erosions and synovitis as seen in rheumatoid arthritis. Arthritis Rheum (2004) 1.49
Quantification of cleaved beta2-microglobulin in serum from patients undergoing chronic hemodialysis. Clin Chem (2005) 1.49
[Fibromyalgia, diagnosis and prevalence. Are gender differences explainable?]. Ugeskr Laeger (2009) 1.48
Validity of rheumatoid arthritis diagnoses in the Danish National Patient Registry. Eur J Epidemiol (2004) 1.48
Mortality and predictors of mortality in rheumatoid arthritis--a role for mannose-binding lectin? J Rheumatol (2010) 1.46
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis (2014) 1.45
Vaccination against encapsulated bacteria in hereditary C2 deficiency results in antibody response and opsonization due to antibody-dependent complement activation. Clin Immunol (2012) 1.42
Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway. Infect Immun (2008) 1.42
Exploring the sialiome using titanium dioxide chromatography and mass spectrometry. Mol Cell Proteomics (2007) 1.38
C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum (2009) 1.37
Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum (2007) 1.36
Selective IgA deficiency in autoimmune diseases. Mol Med (2011) 1.31
Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum (2013) 1.28
A genetic basis of susceptibility to acute pyelonephritis. PLoS One (2007) 1.28
Sample handling for mass spectrometric proteomic investigations of human sera. Anal Chem (2005) 1.23
Socioeconomic status and risk of rheumatoid arthritis: a Danish case-control study. J Rheumatol (2006) 1.23
Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. Medicine (Baltimore) (2005) 1.22
The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis Res Ther (2005) 1.17
Olfactomedin 4 defines a subset of human neutrophils. J Leukoc Biol (2011) 1.15
Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus. Arthritis Rheum (2011) 1.13
The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf (2008) 1.12
Characterization of the human cerebrospinal fluid phosphoproteome by titanium dioxide affinity chromatography and mass spectrometry. Anal Chem (2008) 1.11
Proteome profiling of human neutrophil granule subsets, secretory vesicles, and cell membrane: correlation with transcriptome profiling of neutrophil precursors. J Leukoc Biol (2013) 1.09
Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populations. Eur J Hum Genet (2012) 1.09
Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int (2012) 1.09
Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum (2011) 1.08
Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol (2009) 1.07
Immunoglobulin deficiencies and susceptibility to infection among homozygotes and heterozygotes for C2 deficiency. J Clin Immunol (2003) 1.06
Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother (2014) 1.06
Genetic, molecular and functional analyses of complement factor I deficiency. Eur J Immunol (2009) 1.04
Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis (2010) 1.04
Association of a CD24 gene polymorphism with susceptibility to systemic lupus erythematosus. Arthritis Rheum (2007) 1.03
Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.03
Recent applications of affinity interactions in capillary electrophoresis. Electrophoresis (2006) 1.03
Papillon-Lefèvre syndrome patient reveals species-dependent requirements for neutrophil defenses. J Clin Invest (2014) 1.03
A candidate gene study of the type I interferon pathway implicates IKBKE and IL8 as risk loci for SLE. Eur J Hum Genet (2010) 1.01
Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis Rheum (2006) 1.01
Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis (2013) 1.01
The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease. Neurobiol Aging (2008) 0.99
A 3'-untranslated region variant is associated with impaired expression of CD226 in T and natural killer T cells and is associated with susceptibility to systemic lupus erythematosus. Arthritis Rheum (2010) 0.99
Complement analysis in the 21st century. Mol Immunol (2007) 0.98
The systemic lupus erythematosus-associated PDCD1 polymorphism PD1.3A in lupus nephritis. Arthritis Rheum (2004) 0.98
Complement in the immunopathogenesis of rheumatic disease. Nat Rev Rheumatol (2012) 0.98
Complement factor I deficiency associated with recurrent infections, vasculitis and immune complex glomerulonephritis. Scand J Infect Dis (2005) 0.97
Gene-environment interactions in the aetiology of systemic lupus erythematosus. Autoimmunity (2007) 0.95
Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther (2013) 0.94
High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum (2011) 0.94
Design of recombinant antibody microarrays for serum protein profiling: targeting of complement proteins. J Proteome Res (2007) 0.94
Cu(II) mediates kinetically distinct, non-amyloidogenic aggregation of amyloid-beta peptides. J Biol Chem (2011) 0.94
Serum levels of ficolin-3 (Hakata antigen) in patients with systemic lupus erythematosus. J Rheumatol (2009) 0.93
Fine mapping and conditional analysis identify a new mutation in the autoimmunity susceptibility gene BLK that leads to reduced half-life of the BLK protein. Ann Rheum Dis (2012) 0.92
Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus. Arthritis Res Ther (2011) 0.92
IgG glycan hydrolysis by endoglycosidase S diminishes the proinflammatory properties of immune complexes from patients with systemic lupus erythematosus: a possible new treatment? Arthritis Rheum (2012) 0.92
Critical role for complement receptor 3 (CD11b/CD18), but not for Fc receptors, in killing of Streptococcus pyogenes by neutrophils in human immune serum. Eur J Immunol (2005) 0.92
Immunoglobulin G (IgG) anti-tissue transglutaminase antibodies used as markers for IgA-deficient celiac disease patients. Clin Diagn Lab Immunol (2005) 0.92
Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord (2011) 0.91
Combination of autoantibodies against different histone proteins influences complement-dependent phagocytosis of necrotic cell material by polymorphonuclear leukocytes in systemic lupus erythematosus. J Rheumatol (2012) 0.91
Analysis of HLA DR, HLA DQ, C4A, FcgammaRIIa, FcgammaRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcgammaRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility. Arthritis Res Ther (2004) 0.90
Dimerization and oligomerization of the chaperone calreticulin. Eur J Biochem (2003) 0.90
Double role of mannose-binding lectin in relation to carotid intima-media thickness in patients with rheumatoid arthritis. Mol Immunol (2009) 0.90
Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP. Ann Rheum Dis (2012) 0.90
Unique protein signature of circulating microparticles in systemic lupus erythematosus. Arthritis Rheum (2013) 0.90